The Cancer Research UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies

European Journal of Cancer

Volumn 40, Issue 6, 2004, Pages 899-906

  Newell, D R ^a   Silvester, J ^a   McDowell, C ^a   Burtles, S S ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ABIRATERONE; AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; ANTINEOPLASTIC AGENT; BIOTRANSDOX; CAMPTOTHECIN; CB 7630; COMBRETASTATIN A4; DOXORUBICIN; IDOXIFENE; LIMONENE; N [[5 [2 (2 AMINO 4,6,7,8 TETRAHYDRO 4 OXO 1H PYRIMIDO[5,4 B][1,4]THIAZIN 6 YL)ETHYL] 2 THIENYL]CARBONYL]GLUTAMIC ACID; O' BROMOTHENYLGUANINE; PACLITAXEL; PACLITAXEL POLIGLUMEX; PYRIDOGLUTETHIMIDE; SP 1049 C; SUBSTANCE P ANTAGONIST; SUBSTANCE P ANTAGONIST G; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALOPECIA; ANIMAL EXPERIMENT; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER PAIN; CANCER THERAPY; CARDIOTOXICITY; CLINICAL RESEARCH; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG DOSE REGIMEN; DYSPNEA; EXPERIMENTAL ANIMAL; FACIAL FLUSHING; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HEADACHE; HOT FLUSH; HUMAN; HYPERSENSITIVITY; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; LETHARGY; LIVER TOXICITY; MALAISE; MALE; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUROTOXICITY; NONHUMAN; PHLEBITIS; PRIORITY JOURNAL; RESEARCH ETHICS; RODENT; SAFETY; SCROTAL PAIN; SIDE EFFECT; SKIN TOXICITY; SPECIES; STOMATITIS; TASTE DISORDER; TOXICITY; TOXICOLOGY; VISUAL DISORDER; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MICE; NEOPLASMS; RATS;

EID: 1942518871     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.12.020     Document Type: Article

References (22)

1. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use Official Journal L 121, 01/05/2001 P. 0034 - 0044.
2. Newell D.R., Burtles S.S., Fox B.W., Jodrell D.I., Connors T.A. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics. British Journal of Cancer. 1999:1999;81. 760-768.
3. Tomaszewski JE. Multi-species toxicology approaches for oncology drugs: The US perspective. European Journal of Cancer, 2004.
4. Committee for Proprietary Medicinal Products. Notes for Guidance on the Pre-clinical Evaluation of Anticancer Medicinal Products. CPMP/SWP/997/96. http://eudra.org/emea.html.
5. Joint Steering Committee of the EORTC and CRC General guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. European Journal of Cancer. 26:1990;411-414.
6. Burtles S.S., Newell D.R., Henrar R.E.C., Connors T.A. Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. European Journal of Cancer. 31A:1995;408-410.
7. Haynes B.P., Jarman M., Dowsett M.et al. Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6- dione in patients with postmenopausal breast cancer. Cancer Chemotherapy and Pharmacology. 27:1991;367-372.
8. 17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. British Journal of Cancer 2004, In press.
9. Coombes R.C., Haynes B.P., Dowsett M.et al. Idoxifene. Report of a Phase I study in patients with metastatic breast cancer Cancer Research. 55:1995;1070-1074.
10. Bissett D., McLeod H.L., Sheedy B.et al. Phase I dose-escalation and pharmacokinetic study of a novel folate analogue. British Journal of Cancer. 84:2001;308-312.
11. Rustin G.J.S., Galbraith S.M., Anderson H.et al. Phase I clinical trial of weekly combretastain A4 phosphate. Clinical and pharmacokinetic results Journal of Clinical Oncology. 21:2003;2815-2822.
12. Rustin G.J.S., Bradley C., Galbraith S.M.et al. 5,6-Dimethylxanthone acetic acid (DMXAA), a novel antivascular agent. Phase I clinical and pharmacokinetic study British Journal of Cancer. 88:2003;1160-1167.
13. 6-alkylguanine-DNA alkyltransferase (ATase) depletion Proceedings American Association of Cancer Research. 41:2000;609.
14. Beale P., Judson I., O'Donnell A.et al. A Phase I and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473). British Journal of Cancer. 88:2003;1128-1134.
15. Seymour L.W., Ferry D.R., Anderson D.et al. Hepatic drug targeting. Phase I evaluation of polymer-bound doxorubicin Journal of Clinical Oncology. 20:2002;1668-1676.
16. TM), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a Phase I study. European Journal of Cancer. 38(Suppl 7):2002;S34.
17. Bissett D, Cassidy J, de Bono JS, et al. Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148) a polymeric derivative of camptothecin (CPT). Journal of Clinical Oncology 2004, In press.
18. Vigushin D.M., Poon G.K., Boddy A.et al. Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 42:1998;111-117.
19. Clive S., Webb D.J., MacLellan A.et al. Forearm blood flow and local responses to peptide vasodilators. A novel pharmacodynamics measure in a Phase I trial of antagonist G, a neuropeptide growth factor antagonist Clinical Cancer Research. 7:2001;3071-3078.
20. Danson S, Ferry D, Alakhov V, et al. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP4019C) in patients with advanced cancer. British Journal of Cancer 2004, In press.
21. Newell D.R., Searle K.M., Westwood N.B., Burtles S.S. Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK. British Journal of Cancer. 89:2003;437-454.
22. Double J., Barrass N., Barnard N.D., Navaratnam V. Toxicity testing in the development of anticancer drugs. The Lancet Oncology. 3:2002;438-442.